All right, everyone. We'll be getting started. My name is Noah Barrow. I'm an equity research associate here at Jefferies, representing Dennis Ding, who covers biotech and spec pharma. I have the pleasure of being with the Apotex team today. I'd like to introduce the CEO, Jeff Watson, and also the CFO, Brian McClelland. Thank you for joining us here at the conference. I think before we really dig into it's been an exciting year. You have the IPO, so maybe start us off at a high level, some of the key milestones that you'd like to really take us through from the past year.
Yeah. Thanks, Noah, and great to see everybody. Welcome. We do find ourselves in a unique position here. We're five months on from our IPO. We had kind of laid that thesis out on our strategy to our investors, and now we're in a position to really speak about it, if you will, with a report card of how we're doing it. We have found those first five months to be quite fruitful for the organization. What we're seeing is really our company executing against that strategy. As we laid out the core strategy of the company and where we thought we would be delivering product launches-
the diversification across the portfolio, we have seen tremendous success there. The launch calendar is delivering. The diversification across products and geographies continues, and we're seeing tremendous momentum on the productivity initiative. Five months in, we feel very good. We'll remain humble as we move through this journey, but we have tremendous momentum, and it really is a story about executing on our strategy now, which is in place, and we'll continue to update and modify that as it goes. But we're very comfortable with where we're at as we move forward.
Yeah. No, absolutely. Then a little bit more so on that strategy part. How are you really thinking about that in terms of the geographies? Then also, there seems to be three categories that your products really prioritize with Apotex. So if you can go a little bit more and provide some color on that.
Yeah, that's great. So the strategy for Apotex in terms of the journey of health is really anchoring in our Canadian market, which is our home market. The company's been there for 52+ years, and we really know the market well. Our R&D focus strategy, regulatory IP, it all really emanates from there. When we think of the corridor that we compete in terms of the Americas, that's really our focus. So we think of Canada as an anchoring market, think about that market as a market where we're wide and diverse with over 600 products in the market. The U.S. market, which we've been serving that market for a long time, I'll say 30 years pretty much now. We have a very targeted approach to that market.
So we'd like to think about products that are more complex, more specific in nature, products that we feel we have good strategy in place around IP, around our regulatory strategy, but once again, a narrower portfolio, 130-odd products in that market. We go into the LATAM market. Once again, we've got assets in Mexico. These are markets that we've been in for many, many years as well, but we will take a more targeted approach on those markets. So, we're going wide and into more focus. The product lines, which we call our lines of business, are really focused on conventional generics, which really, historically, that's been really the roots of the company, developing products, time to market, being first-to-market on our conventional generics. Then we think of a specialty generic product portfolio, which we've been quite successful with, and we'll continue to work there.
Then brands and biosimilars is really as we move up the value chain. Really since 2023, we've been building out that value chain of higher value products in the brands and biosimilars with a couple acquisitions that we've anchored ourselves in Canada, and a most recent acquisition which we acquired seven brand assets in the U.S. So we feel good how we're moving through these product lines. If we think about the longer term five-year window, you start to see the diversification across these product lines around 1/3 in each category. So we'll continue to invest in the higher value products, but we're not abandoning the roots of the company, which really has been launching those conventional specialty generics, being first-to-market, taking advantage of the expertise that we've pulled forward in the company through the many years.
No, absolutely. Then maybe taking a step back a little bit, but going to the guidance raise. Is there, for example, you mentioned some of these higher value specialty generics and also the branded products. How are you really seeing the product mix really shift in terms of where your expectations are?
Well, we continue to see. I mean, we've spent a lot of time talking about semaglutide.
Yes
If we want to talk about specialty products. That's a good example for the company of launching a complex specialty product with a multi-step supply chain and being first to market in our home market. In Canada and really serving the market. There are some market dynamics that we've been able to take advantage of, and we continue to build into that. So that's a perfect example. But if we think to the U.S. market, we've had some first-to-file products that we've launched, sitagliptin. We've got a multivitamin. So the diversification of the portfolio is working quite nicely, and we're continuing to add product opportunities on the brands and biosimilars. We've just filed pertuzumab, so we're going to see the biosimilar market for us add assets and potentially double in the next five years there. We're continuing to work with the Searchlight portfolio as well.
So we've got good momentum in those areas, and really, the high-value specialty products were showing up first to market. Really targeting around 70% of the portfolio delivering that first-to-market launch, really concentrating on really where the value is in that portfolio.
Okay, absolutely. Going a bit more into sema, which I think is a pretty big topic for investors right now. You mentioned as well the competitive dynamic shift, and I guess some of the other entrants that you may have been expecting, you didn't really see come to market. How are you really thinking about the sema franchise really moving forward as some of those competitors might enter the market?
Yeah. So we were launching semaglutide with the expectations that we'd be launching with competitors there, and that did not materialize. That said, we have worked hard to build out the supply chain, which we are building momentum there. Just quickly on the numbers, we see a market that has grown 19%. We see as the generics products have come in, we've seen that portfolio, which was roughly around 12 million pens, grow to the tune of 19%, and we're not sure that that's where it stops. I mean, that momentum will continue to build there, as we continue to pull products forward. And we're not building inventory now. We're selling through all our capacity. So we're sitting now with currently 21% share of the overall market.
For us, if we think about competitors, which will show up in the coming months, and we fully expect that they'll show up, for us, that tailwind that we have, the good news for us is we're going to have competitors joining the market in a market that's growing, which typically in a generic space, when products go generic, the market formation is there. But we're now seeing tremendous momentum building, and we're not sure where it stops in terms of this high tide. And I would say lessons learned as you pressurize the supply chain with multiple steps on a sterile injectable product, I mean, you have to be mindful about how you continue to build inventory.
We're fortunate we've got some time in, and we see that inventory building, into the end of the year, and we'll be in a strong position next year as others enter.
Okay.
Maybe I'll add a little bit. While semaglutide is an important product for us, and we're very excited about it, we really step back and look at the breadth of our pipeline that we've launched this year and will be launching over the next five years. We've launched over 61 products so far this year. We have 480 products we have planned to be launched over the next five years, and that's a very diverse set of new products that helps contribute to durable growth. If we think about the revenue that those products have contributed this year, that equates to, through the first half of the year, over 10% of our revenue from in-year revenues from those new product launches, and we expect that to continue over the course of the next five years.
While there are going to be products and our products that perform well in our portfolio, it's the breadth of our launch portfolio that is really contributing to our momentum so far in this year and the momentum that we expect over the next five years.
No, absolutely. Then a bit more then on the breadth. How do you really go about thinking for the internal versus external, I guess, development of these products in your portfolio?
Yeah. I mean, our roots have been established really in the conventional generic, touching into the specialty generic. We've got good formulation capability inside. The roots of the company have been really steep from our founder in R&D, and that linkage to IP and regulatory strategy. Really, when we think about the portfolio and the partnerships, it's really the partnership model for us, which we have really strengthened over the last three and a half years, is really accessing technologies that we may not have in-house.
We'll call it capital light. It's investments we don't need to make. We've got significant partnerships around the globe that we can access products, like a semaglutide is a perfect example. It allows us to be there where we need to be. As we look at kind of the portfolio process, we look at our internal capabilities, where we have expertise, and then where we have partnerships that can augment that. I would think about those partnerships as continuing to build and grow, investments continuing to be made there. We're continuing to strengthen our internal development team. We've got significant talent inside, and we see building out that talent inside to really, as they work in.
If you think of the partnership model for Apotex, many of the partners we have on a co-development basis, we have a lot of integration with our scientific staff, whether it's picking up on a regulatory strategy, whether it's offering some project planning on our R&D side. We tend to try to be very involved with our partnerships, as we build out important products in the portfolio.
By employing that model, we have doubled the size of our pipeline since our fiscal 2023, where we now have about equal the size of externally developed products and internally developed products. What that equates to is not only durable growth for us, but a very strong return on invested capital, as you've heard from Jeff, that those external development partners allow us to get to market faster, at a lower cost, with a lower risk. Our latest four-year trailing average return on capital is over 20%.
Yeah. No, absolutely. Transitioning a little bit to more of an adjacent product would be the Wegovy generic that is coming up. I guess considering the sema launch and how that has been going, how are you thinking about maybe leveraging some of those same partnerships, whether it be payer access to also establish your footprint there, moving forward?
Yeah. We expect to launch SEVMIA, our Wegovy product, before the end of the year. We are launching with one strength. That product will come into the market under the weight loss, the Wegovy product category. Right now, we are competing in the Type 2 diabetes market with our product. I think it just, it really, it kind of increases our breadth of our franchise. Other strengths will round out that portfolio in the coming months and particularly year ahead in terms of various stages of regulatory filing. It really starts to strengthen our positioning in the category. We will be there first. We are fortunate to have that positioning. Once again, we are introducing our product to patients, providing access, and bringing value into the customer channel.
Okay, absolutely. Now going into a bit more on the geographical aspects. For U.S., with Richmond Hill and the ophthalmic business, there has been some recent development there. Maybe starting a little bit back, if you could provide a bit of a background for it, and then where you are really seeing it moving forward in terms of remediation there.
Yeah. The Richmond Hill site is our liquids facility. We produce ophthalmic products there, we produce nasal products there, and we have been shipping from that site into our core markets for many, many years.
That site had a warning letter placed on it in 2025 from FDA with an inspection that took place at that time. Thinking about the site today, the site has been and is fully operational in that timeframe of 2025. We have had Health Canada in the site. We had FDA in the site. Health Canada, at that same period of time, the site had a compliant rating on it. FDA had some observations, really stemming around an older piece of technology we will call Ophtha 2, which we were developing ophthalmic products at that point in time. Post the audit results, we took a voluntary stance to stop selling our ophthalmic products in the U.S. We continue to sell those products in our Canadian business, but we stopped those and began the installation of our Ophtha 3 line. I would say we are on track with that.
We have just had Health Canada in the Richmond Hill site, and we have had a compliant rating. We have got notice from FDA. There is no further action required from us to them in terms of writing. Really, we see the end of the year, we will be asking FDA to come back into the site to inspect and approve the new line. When the new line is approved, we see relaunching those ophthalmic products back into the market. That basket of products were not material to the overall business. Our ability to take a voluntary recall, though, really helped manage the patient and manage the customers, and will allow us to seamlessly move back into the market when the Ophtha 3 is ready post-inspection from FDA. So, we will be ready to ask them in by the end of this calendar year.
While these sales were not particularly any material for us, this is also a good example of the resilience and the diversity of our business. As we look at this year's forecast, we have just increased our guidance to 9%-10% in revenue growth for the year, and that includes the impact of pausing our ophthalmic sales into the U.S.
No, absolutely. I guess a little bit more on that as well. There was the, I guess, tariff impact as well. I know that, I believe from what you said, that most of it has been recovered, but how are you really seeing those tariffs play into the future of the United States franchise?
Well, it's been an ongoing conversation around tariffs for some time. Structurally, our organization, I'll need to start at the top. Number one, we understand domestic policy to have a sovereign pharmaceutical supply chain, so we certainly understand the goals of the administration. I would say the Canadian government is equally as concerned that they make sure that they have good domestic supply as well. So, we're certainly aligned at the policy level, and what we spend time thinking about is how does this roll out and what does that look like when the administration's ready to roll that out? Our assets are primarily North American-based. We do have a large site in India, but we have strong manufacturing sites right in Canada, within an hour of the border.
These sites have service levels of over 95%, and they've been shipping into the U.S. for three decades now. So, well familiar with the site. We understand what the administration's trying to do. We also think we're well-positioned with other options we may have as we move forward. We have options to strengthen certain partnerships in the U.S., make targeted acquisitions that make sense to us. We've got room on the balance sheet to make these types of decisions. But as we start to learn more from where the administration's at, I think we'll make those bets. But we're very closely aligned. Our president in the U.S., Christine Baeder, has been working very closely with the association and also as an individual executive, providing some level of, I guess, dialogue from an industry perspective. So, I think we're hyper-focused on it.
We are looking for more clarity, but we ultimately feel we're well-positioned, and we've certainly seen, from some of the comments that were made months back, we have seen no further comments around that or follow-up to that. And I would say if you think of the tariffs, and some of you follow some of the decisions that happened up to date, generics have been exempt from those conversations around tariffs.
No, absolutely. I guess also similarly, the Cumberland, I guess, business. How are you thinking about it as it expands the United States franchise and some of the capabilities that you may not have had before, and some of the assets that you're now bringing into the Apotex portfolio? Where do you see that going in the near-term future?
Well, this is an exciting opportunity for the company. It is really on that journey of health, and it really speaks to how the company is transitioning into the next phase of its own journey. And I think as we look at a Cumberland-type acquisition, it gives us a great platform to build off of. We think of, say, portfolio transactions. We can now look at transactions that will add to the portfolio. It is in a space that we are comfortable with. It is the right size transaction for this stage of the organization for Apotex, and it gives us lots of momentum, and it gives us other options in the U.S. to continue to build on it.
We are very focused on that asset and what we can do more to augment it, better prepare it to grow, and that will come with some level of investment along the way that we are continually looking at as we speak.
Then I guess a little bit more on the characteristics in terms of identifying those opportunities that are the most attractive for Apotex. I guess, where are you really looking for in terms of, I guess, contributing to your portfolio and more so of the long-term vision of where you really see Apotex going?
Yeah, we see in our core markets on strategy, if we start in Canada, building out that biosimilar portfolio, we see that doubling in the next five years. We have added three products this year. We will continue to focus there. We have a nice franchise in our Searchlight business. We will continue to invest in that portfolio and broaden that opportunity, which really starts to widen with a health and wellness business that we picked up at the end of 2024, CanPrev. That market is doing well. It is now starting to make its way in a very measured way into the U.S. We have got four states that we are looking at, both at a retail and digital level, but really at the higher value end of those products. So, we will continue to invest in those areas.
Brian mentioned the diversification part of our strategy becomes very important. On conventional generics and on specialty generics, we look at a window of loss of exclusivity that we haven't run into this for a few years, maybe going back to 2013, 2014. You'll hear words like patent cliff. We feel we're in another five-year window for our two core markets, Canada and the U.S. We see tremendous opportunity there. The opportunity there for Apotex will be to execute, be first to market 70% of the time on those LOEs, and drive into the value. We've got three or four areas that really speak to the diversification in that market and in the U.S. market.
The difference with the U.S. market is we just have to be more targeted, more disciplined, and it speaks to that breadth of the portfolio of 130 products versus 600 products in the Canadian market.
Yeah, absolutely. Shifting gears also a little bit then, you briefly touched on the axitinib launch and then also pertuzumab's coming up. How are you really thinking about the oncology portfolio and really, I guess, the footprint that that will have as well moving forward in terms of those cases?
Yeah, it's a core area, therapeutic area, actually in both markets. In the Canadian market, it's really where we focus our biosimilar targets on oncology and ophthalmology. In the U.S., the oncology franchise is very strong for us. The nasals are very strong, and we've launched several first-to-files in these, we'll call it the nib product family, products which are oncologies, which we had developed some years ago. We'll continue to strengthen that, and in some of the other opportunities that we're looking at on the higher values, we'll continue to build out those same therapeutic areas. We may add an area or two as we go. We're fairly comfortable that we are positioned well, though, now to drop assets into these therapeutic areas, whether we're developing internal, but also looking for product expansion transactions.
Okay, absolutely. Then I guess in the last couple of minutes, I guess I really want to touch on a bit more of the capital allocation as well. So, currently at about a leverage of 2.3x, which is below the 2.5x target. So I guess how should investors really be thinking about capital allocation and mergers and acquisitions going forward? I guess more so on your balance sheet as well, what you really see in the near-term future?
So as we look at our capital structure, our priority is focused on growth. We're looking to invest to support and expand our return on invested capital that we're providing back to shareholders. We see a lot of opportunities to do that through M&A, which is not in our midterm forecasts right now. As we look forward to this year and the next year, we're looking to build upon internal development and external development, including other transactions like the Cumberland one that we just completed, that we can fund through our strong cash generation. Right now, we do offer a modest dividend. We don't have any specific plans for share buybacks at this point in time, as we see that we can generate a much stronger return on our invested capital from putting our capital to work in additional growth.
No, absolutely. Then I guess thinking about the diversification of the broader portfolio, but some of the expansion that you are seeing in the branded and also the more complex generics, how are you really seeing that kind of play out in terms of the gross margins and then as it trickles down, I guess, to the lower line as well?
Well, as we look at our gross margins, this is where our journey of health and product diversity really come into play. As we move from conventional generics through to specialty generics, through to brands and biosimilars, we see our margins improving, and that's exciting for us. We've seen that so far this year in our execution, and we have that planned in the future as well as our midterm goals are to see margins improving to the low to mid 30% over time, over the next five years or so.
Yeah, no, absolutely. Well, that would be all the questions that I have, but it was a pleasure to have you all here, and thank you.
Thank you.
Thank you.
Thank you.